• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

    6/2/25 6:00:00 AM ET
    $GSK
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GSK alert in real time by email
    • Definitive agreement to result in one-time $225 million cash payment 
    • Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved
    • $225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022, and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billion
    • First outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value; Board remains committed to returning excess capital to shareholders

    DUBLIN, June 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced that it has entered into a definitive agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta ("Trelegy") to GSK (NYSE:GSK) for $225 million in cash.

    Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)

    "Through this agreement with GSK to monetize our outer-year Trelegy royalties, we are translating our long-standing confidence in Trelegy's sustained success into immediate value for Theravance Biopharma shareholders," said Rick E Winningham, CEO of Theravance Biopharma. "Our initial 2022 sale of Trelegy royalty interests generated $1.1 billion in upfront cash, strengthening our balance sheet and enabling us to return significant capital to shareholders. Our decision to retain future Trelegy royalties and potential milestones in the 2022 transaction reflected our confidence in the product's enduring value and commitment to maximize the value of the royalty interest for our shareholders. This latest agreement with GSK, resulting from the ongoing work of the Strategic Review Committee and the company's senior management, further validates this strategy, and comes alongside our continued work to grow YUPELRI and advance ampreloxetine towards potential regulatory approval and launch."

    Theravance Biopharma's economic interest in Trelegy originates from a 2002 collaboration agreement with GSK, in which Theravance Biopharma's predecessor pooled with GSK its long-acting beta agonist (LABA) assets in exchange for milestones and royalties on LABA-containing combination products subsequently developed and commercialized by GSK, including Trelegy. In 2022, Theravance Biopharma sold its economic interest in the Trelegy royalties to Royalty Pharma in exchange for $1.1 billion upfront and potential sales related milestone payments of up to $250 million in the aggregate, while retaining the right to receive 85% of Trelegy royalties for sales of Trelegy from and after 2029 (ex-U.S.) and 2031 (U.S.) ("Outer Year Royalties").

    Under the terms of the agreement announced today, Theravance Biopharma will receive $225 million in cash for the sale of the Outer Year Royalties. The Company retains its right to receive up to $150 million in remaining Trelegy sales related milestones in 2025 and 2026 from Royalty Pharma:

    • $50 million if FY 2025 global net sales reach ~$3.41 billion (approx. -1% vs. 2024)
    • $100 million if FY 2026 global net sales reach ~$3.51 billion (approx. +2% vs. 2024)

    Theravance Biopharma's financial guidance for 2025 remains unchanged.

    This transaction represents the first outcome of the ongoing efforts of the Strategic Review Committee (the "Committee") of the Board of Directors. Theravance Biopharma announced on November 12, 2024, that the Board of Directors had formed the Committee, composed entirely of independent directors, to assess all strategic alternatives available to the Company. The Company remains focused on disciplined capital allocation and returning excess cash to shareholders. The Committee will continue to evaluate a range of alternatives to further enhance shareholder value, though there can be no assurance that additional transactions will occur.

    Advisors

    Lazard acted as exclusive financial advisor, and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to Theravance Biopharma.

    About Theravance Biopharma

    Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

    For more information, please visit www.theravance.com.

    THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

    YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

    TRELEGY and ELLIPTA are registered trademarks of the GSK group of companies.

    Forward-Looking Statements

    This press release will contain certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations, and future events. Theravance Biopharma intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: the Company's expectations regarding its future profitability, expenses and uses of cash, the Company's goals, designs, strategies, plans, potential, and objectives, future growth of YUPELRI sales, future milestone and royalty payments, the ability to provide value to shareholders, the Company's regulatory strategies and timing of clinical studies, potential or possible safety, efficacy or differentiation of our investigational therapy,  ongoing review activities of the Strategic Review Committee and contingent payments due to the Company from the sale of the Company's Trelegy royalty interests to Royalty Pharma. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: factors that could increase the Company's cash requirements or expenses beyond its expectations and any factors that could adversely affect its profitability, whether the Trelegy milestone thresholds can be achieved, delays or difficulties in commencing, enrolling or completing clinical studies, the potential that results from clinical or non-clinical studies indicate the Company's product candidates or product are unsafe, ineffective or not differentiated, risks of decisions from regulatory authorities that are unfavorable to the Company, dependence on third parties to conduct clinical studies, delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with or relying on third parties to discover, develop, manufacture and commercialize products, and risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate technical expertise and supporting infrastructure, the ability of the Company to protect and to enforce its intellectual property rights, volatility and fluctuations in the trading price and volume of the Company's shares, and general economic and market conditions. Other risks affecting Theravance Biopharma are in the Company's Form 10-Q filed with the SEC on May 12, 2025, and other periodic reports filed with the United States Securities Exchange Commission (the "SEC"). In addition to the risks described above and in Theravance Biopharma's filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma's results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

    Contact:

    [email protected]

    650-808-4045

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-inc-sells-remaining-royalty-interest-in-trelegy-ellipta-to-gsk-for-225-million-302470412.html

    SOURCE Theravance Biopharma, Inc.

    Get the next $GSK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GSK
    $TBPH

    CompanyDatePrice TargetRatingAnalyst
    GSK plc
    $GSK
    6/3/2025Buy → Hold
    Berenberg
    GSK plc
    $GSK
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    GSK plc
    $GSK
    2/12/2025Equal-Weight
    Morgan Stanley
    GSK plc
    $GSK
    11/15/2024Buy → Hold
    Deutsche Bank
    GSK plc
    $GSK
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    GSK plc
    $GSK
    10/31/2024Buy → Neutral
    Guggenheim
    Theravance Biopharma Inc.
    $TBPH
    8/6/2024$15.00 → $10.00Outperform → Market Perform
    Leerink Partners
    GSK plc
    $GSK
    7/8/2024Buy → Neutral
    UBS
    More analyst ratings

    $GSK
    $TBPH
    SEC Filings

    See more
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      6/5/25 6:31:56 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      6/4/25 6:23:41 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      6/4/25 6:19:40 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $TBPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • GlaxoSmithKline downgraded by Berenberg

      Berenberg downgraded GlaxoSmithKline from Buy to Hold

      6/3/25 7:26:51 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

      Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

      4/15/25 12:40:46 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on GlaxoSmithKline

      Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight

      2/12/25 7:05:11 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $TBPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

      Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved$225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022, and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billionFirst outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value; Board remains committed to returning exces

      6/2/25 6:00:00 AM ET
      $GSK
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

      If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs2Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 that Spero's development partner, GSK, intends to submit CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) and GSK plc (LSE/NYSE:GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigation

      5/28/25 7:00:00 AM ET
      $GSK
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)

      Nucala is the only approved biologic studied in a wide COPD population with an eosinophilic phenotype characterized by blood eosinophil count (BEC) starting at 150 cells/μL Approval based on the positive MATINEE and METREX phase III trials MATINEE data included reduction of exacerbations leading to hospitalization and/or emergency department visits Nearly 70% of patients in the US who are inadequately controlled on inhaled triple therapy have a BEC ≥150 cells/μL GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinoph

      5/22/25 4:15:00 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $TBPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

      SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)

      11/14/24 9:53:41 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

      SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)

      11/12/24 5:53:05 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GSK plc

      SC 13G/A - GSK plc (0001131399) (Subject)

      11/12/24 4:32:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $TBPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Samaha Eli bought $7,798,440 worth of COM (999,800 units at $7.80) (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      8/9/24 6:02:35 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Samaha Eli bought $13,117,335 worth of COM (1,499,124 units at $8.75) (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      5/3/24 4:19:22 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $TBPH
    Leadership Updates

    Live Leadership Updates

    See more
    • GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

      Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

      5/9/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

      TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

      11/18/24 7:30:00 AM ET
      $GSK
      $MDCX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $TBPH
    Financials

    Live finance-specific insights

    See more
    • Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

      YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 20242CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late summerQuarter-end cash balance of $131 million, with no debtReaffirming all financial guidance metricsDUBLIN, May 8, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial and operational results for the first quarter of 2025.

      5/8/25 4:05:00 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

      DUBLIN , April 24, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please dial (800) 715-9871 from the US or (646) 307-1963 for international callers, using the Conference ID 3369474. Those interested in listening to the conference call live v

      4/24/25 6:00:00 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

      YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 20231FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26% compared with 2023 and triggering a $50 million milestone to Theravance Biopharma2,3CYPRESS study on track to enroll final patient in the open label portion by mid-2025Ended Q4 2024 with $88 million in cash, excluding the $50 million TRELEGY milestone, with cash receipt in February 2025DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial an

      2/26/25 4:05:00 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $TBPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold $264,000 worth of Ordinary Shares (24,000 units at $11.00), decreasing direct ownership by 7% to 336,918 units (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      6/4/25 6:04:21 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 15,364 units of Ordinary Shares, decreasing direct ownership by 0.86% to 1,762,780 units (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      5/22/25 6:44:56 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP & CHIEF FINANCIAL OFFICER Sawaf Aziz covered exercise/tax liability with 9,348 units of Ordinary Shares, decreasing direct ownership by 2% to 364,790 units (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      5/22/25 6:42:52 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care